Cristina Bulai Livideanu, MD, MSc Principal Investigator Centre Hospitalier Universitaire, Service de Dermatologie, Toulouse -France
Kontakt
Clinical Study Coordinator Kontakt: Phone: +33(0)147200014 E-Mail: clinical@ab-science.com» Kontaktdaten anzeigen
Studienlocations (3 von 17)
University Hospital Charité Berlin (Berlin) GermanyNoch nicht rekrutierend» Google-MapsCentre Hospitalier Universitaire d'Amiens Amiens FranceRekrutierend» Google-MapsHospital Jean-Minjoz Besançon FranceRekrutierend» Google-Maps
Grenoble University Hospital Grenoble FranceRekrutierend» Google-MapsHospital Claude Huriez Lille FranceRekrutierend» Google-MapsMarseille University Hospital Timone Marseille FranceRekrutierend» Google-MapsCentre de référence de Mastocytose (CEREMAST) Paris FranceRekrutierend» Google-MapsPoitiers University Hospital Poitiers FranceRekrutierend» Google-MapsCentre Hospitalier Universitaire Toulouse FranceRekrutierend» Google-MapsErasmus University Medical Center Rotterdam NetherlandsRekrutierend» Google-MapsMedical University of Gdańsk Gdańsk PolandRekrutierend» Google-MapsThe University Hospital in Krakow (Szpital Uniwersytecki w Krakowie) Kraków PolandRekrutierend» Google-MapsUniversity Hospital in Bucharest (Spitalul Universitar de Urgență București) Bucharest RomaniaRekrutierend» Google-MapsAlmazov National Medical Research Centre Saint Petersburg Russian FederationRekrutierend» Google-MapsDnipropetrovsk Clinical Association of Emergency Medical Care of Dnipropetrovsk Regional Dnipropetrovs'k UkraineRekrutierend» Google-MapsPrivate Enterprise Private Manufacturing Company Acinus Poltava UkraineRekrutierend» Google-MapsGuy's and St Thomas' NHS Foundation Trust London United KingdomRekrutierend» Google-Maps
1. Cumulative response (3R75%) (Time Frame - 24 weeks): Cumulative response in at least one of three severe baseline symptoms of mast cell mediator release (pruritus, flushes, or depression). Response was defined as a 75% improvement from baseline for any of these three symptoms. Cumulative response was defined as the number of actual responses between weeks 8 and 24, divided by the total number of possible responses over the same treatment period (ie, with five scheduled visits, each patient had a maximum of five to 15 possible responses depending on the number of severe baseline symptoms).
Secondary outcome:
1. Cumulative response (4R75%) (Time Frame - 24 weeks): Cumulative response in at least one of four severe baseline symptoms of mast cell mediator release (pruritus, flushes, depression, or asthenia). Response is defined as a 75% improvement from baseline for any of these four symptoms. Cumulative response was defined as the number of actual responses between weeks 8 and 24, divided by the total number of possible responses over the same treatment period (ie, with five scheduled visits, each patient had a maximum of five to 20 possible responses depending on the number of severe baseline symptoms).
2. Cumulative response (2R75%) (Time Frame - 24 weeks): Cumulative response in at least one of two severe baseline symptoms of mast cell mediator release (pruritus or flushes). Response is defined as a 75% improvement from baseline for either of these two symptoms. Cumulative response is defined as the number of actual responses between weeks 8 and 24, divided by the total number of possible responses over the same treatment period (ie, with five scheduled visits, each patient had a maximum of five to 10 possible responses depending on the number of severe baseline symptoms).
3. Cumulative response (Time Frame - 24 weeks): Cumulative response on each of the individual handicaps. Response is defined as a 75% improvement from baseline for either of these two symptoms. Cumulative response is defined as the number of actual responses between weeks 8 and 24, divided by the total number of possible responses over the same treatment period.
Experimental: Masitinib & BSC Experimental Arm:
Masitinib (titration to 6.0 mg/kg/day) administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC).
Participants receive masitinib (3.0 mg/kg/day), given orally twice daily, with a dose escalation to 4.5 mg/kg/day after 4 weeks of treatment, followed by dose escalation to 6.0 mg/kg/day after 4 weeks of treatment. Each ascending dose titration is subjected to a safety control.
Placebo Comparator: Placebo & BSC Placebo Comparator:
Matching placebo administered as an add-on to optimal concomitant symptomatic treatment (i.e. best supportive care, BSC)